Bexarotène : interactions médicamenteuses

Acitretin is contraindicated in cases of hypersensitivity (e.g., angioedema, urticaria) to the preparation (acitretin or excipients) or to other retinoids . (notice Acitrétine, Contre-indications)

Because of a potential drug-drug interaction, avoid gemfibrozil use with TARGRETIN [ see Drug Interactions (7) ]. (notice Bexarotène, Mises en garde et précautions)

Avoid concomitant use of isotretinoin and EMROSI because isotretinoin, a systemic retinoid, is also known to cause idiopathic intracranial hypertension. (notice Minocycline, Mises en garde et précautions)

Concomitant use of isotretinoin and tetracycline should be avoided because isotretinoin, a systemic retinoid, is also known to cause pseudotumor cerebri. (notice Tétracycline, Mises en garde)

Tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. (notice Trétinoïne, Contre-indications)

Patients with CTCL who have risk factors for pancreatitis (e.g., prior pancreatitis, uncontrolled hyperlipidemia, excessive alcohol consumption, uncontrolled diabetes mellitus, biliary tract disease, and medications known to increase triglyceride levels or to be associated with pancreatic toxicity) may be at greater risk for pancreatitis associated with TARGRETIN… (notice Bexarotène, Mises en garde et précautions)

Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (notice Chlorure de calcium, Interactions médicamenteuses)

Patients with elevated vitamin A levels may be at increased risk. (notice Élexacaftor, tézacaftor et ivacaftor, Mises en garde et précautions)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (notice Bexarotène, Mises en garde et précautions)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (notice Bexarotène, Mises en garde et précautions)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (notice Bexarotène, Mises en garde et précautions)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (notice Bexarotène, Mises en garde et précautions)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (notice Bexarotène, Mises en garde et précautions)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (notice Bexarotène, Mises en garde et précautions)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (notice Bexarotène, Mises en garde et précautions)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (notice Bexarotène, Mises en garde et précautions)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (notice Bexarotène, Mises en garde et précautions)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (notice Bexarotène, Mises en garde et précautions)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (notice Bexarotène, Mises en garde et précautions)

Patients with elevated vitamin A levels may be at increased risk. (notice Ivacaftor, Mises en garde et précautions)

Monitor and replace thyroid hormone if needed. (notice Bexarotène, Mises en garde et précautions)

Monitor and replace thyroid hormone if needed. (notice Bexarotène, Mises en garde et précautions)

Monitor and replace thyroid hormone if needed. (notice Bexarotène, Mises en garde et précautions)

Monitor patients receiving XATMEP with other potential hepatotoxins (e.g., azathioprine, retinoids, and sulfasalazine) for possible signs of hepatotoxicity. (notice Méthotrexate, Interactions médicamenteuses)

The effect of ORLISTAT on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time [see Clinical Pharmacology (12.3) , and Warnings and Precautions (5.1) ] . (notice Orlistat, Interactions médicamenteuses)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (notice Bexarotène, Mises en garde et précautions)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (notice Bexarotène, Mises en garde et précautions)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (notice Bexarotène, Mises en garde et précautions)

Monitor and replace thyroid hormone if needed. (notice Bexarotène, Mises en garde et précautions)

Monitor and replace thyroid hormone if needed. (notice Bexarotène, Mises en garde et précautions)

Monitor and replace thyroid hormone if needed. (notice Bexarotène, Mises en garde et précautions)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (notice Bexarotène, Mises en garde et précautions)

Atorvastatin was used in 48% (73/152) of patients with CTCL. (notice Bexarotène, Mises en garde et précautions)

Atorvastatin was used in 48% (73/152) of patients with CTCL. (notice Bexarotène, Mises en garde et précautions)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (notice Bexarotène, Interactions médicamenteuses)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (notice Bexarotène, Interactions médicamenteuses)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (notice Bexarotène, Interactions médicamenteuses)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (notice Bexarotène, Interactions médicamenteuses)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (notice Bexarotène, Interactions médicamenteuses)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (notice Bexarotène, Interactions médicamenteuses)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (notice Bexarotène, Interactions médicamenteuses)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (notice Bexarotène, Interactions médicamenteuses)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (notice Bexarotène, Interactions médicamenteuses)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (notice Bexarotène, Interactions médicamenteuses)

Vitamin A Based on a case report in one patient receiving combination therapy with all-trans-retinoid acid (an acid form of vitamin A) and fluconazole, central nervous system (CNS) related undesirable effects have developed in the form of pseudotumor cerebri, which disappeared after discontinuation of fluconazole treatment. (notice Fluconazole, Interactions médicamenteuses)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (notice Bexarotène, Interactions médicamenteuses)

Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (notice Gluconate de calcium, Interactions médicamenteuses)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (notice Bexarotène, Interactions médicamenteuses)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (notice Bexarotène, Interactions médicamenteuses)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (notice Bexarotène, Interactions médicamenteuses)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (notice Bexarotène, Interactions médicamenteuses)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (notice Bexarotène, Interactions médicamenteuses)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (notice Bexarotène, Interactions médicamenteuses)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (notice Bexarotène, Interactions médicamenteuses)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (notice Bexarotène, Interactions médicamenteuses)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (notice Bexarotène, Interactions médicamenteuses)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (notice Bexarotène, Interactions médicamenteuses)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (notice Bexarotène, Interactions médicamenteuses)